Interferon-Beta Exposure During First Trimester in Women with Multiple Sclerosis - A Prospective Cohort Study from the German Multiple Sclerosis and Pregnancy Registry (S24.005)

Conclusion IFN-beta exposure during early pregnancy does not decrease the mean birth weight and does not lead to preterm birth. Other pregnancy outcomes were similar between the exposed and unexposed groups. Our study provides further reassurance that IFN-beta has not to be withdrawn before pregnancy in women with MS.Disclosure: Dr. Thiel has nothing to disclose. Dr. Menck has nothing to disclose. Dr. Elias-Hamp has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Healthcare, Almirall, Novartis, Teva, and Genzyme as a speaker. Dr. Gold has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience. Dr. Hellwig has received personal compensation for activities with Bayer Schering, BiogenIdec, Merck Serono, Teva Aventis and Novartis as a speaker. Dr. Hellwig has received research support from the German Research Foundation.
Source: Neurology - Category: Neurology Authors: Tags: Clinical Outcomes and Treatment Strategies in Multiple Sclerosis Source Type: research